A phase III clinical study of EB-101 gene therapy for patients with Epidermolysis Bullosa.
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2017
At a glance
- Drugs EB 101 (Primary)
- Indications Epidermolysis bullosa
- Focus Registrational; Therapeutic Use
- Sponsors Abeona therapeutics
- 29 Aug 2017 According to an Abeona Therapeutics media release, Company continues to engage the FDA on the final Phase 3 clinical trial design, and will provide an update on the program in the coming months.
- 21 Jul 2017 New trial record
- 18 Jul 2017 According to an Abeona Therapeutics media release, company plans to commence this study in early 2018.